STO · FLUI.ST
Fluicell AB (publ)
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
Loading market information…
STO · GABA.ST · SEK
Stock price, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Gabather AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 75.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Gabather AB (publ)’s next earnings report is currently expected on Nov 27, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gabather AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 0.01+SEK 0.00 (+6.98%)
Spermosens AB’s quoted price sits in the upper half of its reported 52-week range, 23.33% below the high.
SEK 1.33-SEK 0.04 (-2.92%)
ODI Pharma AB’s quoted price sits in the lower half of its reported 52-week range, 75.6% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.00-SEK 0.00 (-5.26%)
S2Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.0% below the high.
SEK 0.02SEK 0.00 (0.0%)
LIDDS AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.7% below the high.
SEK 0.00-SEK 0.00 (-16.67%)
Quia Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.33% below the high.
SEK 0.21-SEK 0.12 (-35.15%)
ProstaLund AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 98.2% below the high.
